Shenzhen Salubris Pharmaceuticals Co Ltd Cash Flow Reinvestment Rate
Shenzhen Salubris Pharmaceuticals Co Ltd cash flow reinvestment rate. Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a Cash Flow Reinvestment Rate of 0.73x as of September 2025, reinvesting CN¥292.24 Million (capex CN¥292.24 Million ) from operating cash flow of CN¥400.70 Million. See 002294 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
Cash flow reinvestment rate of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024. Historical reinvestment intensity for Shenzhen Salubris Pharmaceuticals Co Ltd across 19 annual periods. Explore Shenzhen Salubris Pharmaceuticals Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Shenzhen Salubris Pharmaceuticals Co Ltd Cash Flow Reinvestment Rate by Year (2006–2024)
Shenzhen Salubris Pharmaceuticals Co Ltd cash flow reinvestment rate by year from 2006 to 2024. Year-by-year capital reinvestment analysis for Shenzhen Salubris Pharmaceuticals Co Ltd. For the full cash flow conversion analysis, see Shenzhen Salubris Pharmaceuticals Co Ltd cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.29x | CN¥1.53 Billion | CN¥1.19 Billion | CN¥624.81 Million | ▼ -45.2% |
| 2023 | 2.35x | CN¥2.04 Billion | CN¥869.79 Million | CN¥671.00 Million | ▲ +77.9% |
| 2022 | 1.32x | CN¥1.28 Billion | CN¥970.80 Million | CN¥598.96 Million | ▲ +171.4% |
| 2021 | 0.49x | CN¥576.03 Million | CN¥1.18 Billion | CN¥482.50 Million | ▼ -23.0% |
| 2020 | 0.63x | CN¥867.50 Million | CN¥1.37 Billion | CN¥642.47 Million | ▲ +39.8% |
| 2019 | 0.45x | CN¥680.11 Million | CN¥1.51 Billion | CN¥457.19 Million | ▼ -19.3% |
| 2018 | 0.56x | CN¥749.80 Million | CN¥1.34 Billion | CN¥332.87 Million | ▼ -33.3% |
| 2017 | 0.84x | CN¥1.22 Billion | CN¥1.46 Billion | CN¥331.67 Million | ▲ +55.1% |
| 2016 | 0.54x | CN¥775.06 Million | CN¥1.43 Billion | CN¥245.06 Million | ▲ +33.7% |
| 2015 | 0.40x | CN¥426.57 Million | CN¥1.06 Billion | CN¥235.57 Million | ▲ +97.7% |
| 2014 | 0.20x | CN¥200.65 Million | CN¥982.25 Million | CN¥200.65 Million | ▼ -68.0% |
| 2013 | 0.64x | CN¥427.20 Million | CN¥668.52 Million | CN¥427.20 Million | ▲ +16.2% |
| 2012 | 0.55x | CN¥286.75 Million | CN¥521.21 Million | CN¥286.75 Million | ▼ -40.7% |
| 2011 | 0.93x | CN¥252.60 Million | CN¥272.32 Million | CN¥252.60 Million | ▼ -22.5% |
| 2010 | 1.20x | CN¥223.48 Million | CN¥186.65 Million | CN¥223.48 Million | ▲ +18.5% |
| 2009 | 1.01x | CN¥135.68 Million | CN¥134.28 Million | CN¥135.68 Million | ▲ +28.0% |
| 2008 | 0.79x | CN¥61.48 Million | CN¥77.89 Million | CN¥61.48 Million | ▲ +203.8% |
| 2007 | 0.26x | CN¥13.71 Million | CN¥52.75 Million | CN¥13.71 Million | ▼ -67.9% |
| 2006 | 0.81x | CN¥9.71 Million | CN¥12.00 Million | CN¥9.71 Million | — |